Twist Bioscience (TWST) earnings history
Most recent quarter
- Fiscal period
- Q3 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.56
- EPS estimate
- −$0.49
- EPS surprise
- −13.52%
- Revenue surprise
- +3.37%
- Revenue
- $118.4M
- Revenue estimate
- $114.5M
- Reported
- Aug 3, 2026
Twist Bioscience reported fiscal Q3 2026 results on August 3, 2026. It posted a loss of $0.56 per share, wider than the expected $0.49 loss, a 13.52% miss. Revenue was $118.4 million, ahead of the $114.5 million estimate by 3.37%. A year earlier, in fiscal Q3 2025, the company reported a profit of $0.33 per share. Revenue rose about 23% from $96.1 million.
That Q3 2025 profit is the only profitable quarter in the table; the other 19 were losses. Annual losses narrowed from $4.03 per share in fiscal 2022 to $3.60 in both 2023 and 2024, then to $1.31 in 2025. Revenue grew from $38.0 million in fiscal Q4 2021 to the latest quarter's high. The first three quarters of fiscal 2026 brought $332.8 million, about 20% more than a year earlier. Twist missed the EPS estimate in each of the last four quarters, after beating it in 13 of the 16 before.
Twist reported fiscal Q4 results between November 14 and November 22 in each of the past five years. That points to mid-to-late November 2026 for the next report. It will complete fiscal 2026 and show how the full-year loss compares with fiscal 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Aug 3, 2026 | −$0.49 | −$0.56 | −13.52% | $118.4M | SEC |
| Q2 2026 | May 4, 2026 | −$0.48 | −$0.71 | −48.72% | $110.7M | SEC |
| Q1 2026 | Feb 2, 2026 | −$0.42 | −$0.50 | −17.92% | $103.7M | SEC |
| Q4 2025 | Nov 14, 2025 | −$0.42 | −$0.45 | −8.36% | $99.0M | SEC |
| Q3 2025 | Aug 4, 2025 | −$0.52 | $0.33 | +163.60% | $96.1M | SEC |
| Q2 2025 | May 5, 2025 | −$0.55 | −$0.66 | −20.39% | $92.8M | SEC |
| Q1 2025 | Feb 3, 2025 | −$0.62 | −$0.53 | +15.13% | $88.7M | SEC |
| Q4 2024 | Nov 18, 2024 | −$0.71 | −$0.59 | +17.36% | $84.7M | SEC |
| Q3 2024 | Aug 2, 2024 | −$0.76 | −$1.47 | −92.43% | $81.5M | SEC |
| Q2 2024 | May 2, 2024 | −$0.82 | −$0.79 | +3.15% | $75.3M | SEC |
| Q1 2024 | Feb 2, 2024 | −$0.78 | −$0.75 | +3.44% | $71.5M | SEC |
| Q4 2023 | Nov 17, 2023 | −$0.92 | −$0.81 | +11.85% | $66.9M | SEC |
| Q3 2023 | Aug 4, 2023 | −$1.12 | −$1.01 | +10.21% | $63.7M | SEC |
| Q2 2023 | May 5, 2023 | −$1.13 | −$1.04 | +7.60% | $60.2M | SEC |
| Q1 2023 | Feb 3, 2023 | −$1.13 | −$0.74 | +34.72% | $54.2M | SEC |
| Q4 2022 | Nov 18, 2022 | −$1.25 | −$0.91 | +27.13% | $57.3M | SEC |
| Q3 2022 | Aug 5, 2022 | −$1.29 | −$1.08 | +16.32% | $56.1M | SEC |
| Q2 2022 | May 5, 2022 | −$1.23 | −$1.13 | +8.41% | $48.1M | — |
| Q1 2022 | Feb 4, 2022 | −$1.06 | −$0.91 | +14.46% | $42.0M | — |
| Q4 2021 | Nov 22, 2021 | −$0.80 | −$0.84 | −4.67% | $38.0M | — |
Quarterly revenue
Frequently asked questions
When did Twist Bioscience (TWST) last report earnings?
Twist Bioscience last reported on Aug 3, 2026, covering fiscal Q3 2026.
Did TWST beat earnings estimates?
No. Twist Bioscience reported EPS of −$0.56 for Q3 2026 against a −$0.49 estimate — a 13.52% miss.
How much revenue did TWST report last quarter?
Twist Bioscience reported $118.4M in revenue for Q3 2026, against a consensus estimate of $114.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.